Novel oxazine compound and use for preventing platelet aggregation
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A compound and oxazine technology, applied in the field of medicine, can solve the problems of poor stability and low content of natural flavonoids, and achieve the effect of a simple synthesis method
Inactive Publication Date: 2009-07-22
SHENYANG PHARMA UNIVERSITY
View PDF1 Cites 6 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0006] However, the content of natural flavonoids is low, and the stability of 4-chromanone Mannich bases is poor. We have modified the structures of flavonoids and 4-chromanones, and designed and synthesized a series of oxazines to overcome The aforementioned disadvantages of natural flavonoids and 4-chromanones
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0023] Example 1: 9-phenyl-4,8,9,10-tetrahydroflavone[8,7-e][1,3]oxazine
[0024] Mix 1.2mL 37% formaldehyde aqueous solution with 5mmol aniline dissolved in 2-3mL 95% ethanol, heat to reflux and stir for a few minutes, then add 5mmol 7-hydroxyflavone dissolved in 10mL 95% ethanol, heat to reflux and stir overnight. After cooling, a large amount of white precipitate was precipitated, which was filtered by suction, and finally recrystallized by ethanol to obtain white crystals with a yield of 44%. MS m / z (M): 355.39. 1 HNMR (CDCl 3 ): δ4.61 (2H, s), 6.00 (2H, s), 6.40 (1H, d), 6.60 (3H, m), 6.71 (1H, s), 7.08~7.34 (8H, m). δ
Embodiment 2
[0025] Example 2: 9-Benzyl-4,8,9,10-tetrahydroflavone[8,7-e][1,3]oxazine
[0026] According to the preparation method provided in Example 1, the compound is obtained by reacting 7-hydroxy-flavone with aqueous formaldehyde and benzylamine. Yield: 47%. MS m / z (M): 369.41. 1 HNMR (CDCl 3 ): δ3.62 (4H, s), 5.01 (2H, s), 6.40 (1H, d), 6.60 (3H, m), 6.71 (1H, s), 7.06-7.21 (8H, m).
Embodiment 3
[0027] Example 3: 9-(2-methylphenyl)-4,8,9,10-tetrahydroflavone[8,7-e][1,3]oxazine
[0028] According to the preparation method provided in Example 1, the compound is obtained by reacting 7-hydroxy-flavone with aqueous formaldehyde and 2-methylaniline. Yield: 38%. MS m / z (M): 369.41. 1 HNMR (CDCl 3 ): δ2.35(3H, s), 4.61(2H, s), 6.00(2H, s), 6.40(1H, d), 6.47(2H, m), 6.71(1H, s), 6.89(2H, m), 7.14-7.34 (6H, m).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention pertains to the field of medical technology, relating to an oxazine compound and a medical application thereof; the oxazine compound and an oxazine salt obtained from an addition reaction of pharmaceutically-applicable oxazine acid can be used as a platelet aggregation inhibitor; the oxazine compound has a structural formula shown as above; in a structural formula I and a structural formula II, X can be independently chosen from CH2 and C=0, R1 can be independently chosen from H and a substituted or un-substituted aromatic base, R2 can be independently chosen from H or a substituted or un-substituted aromatic base, and R3 can be independently chosen from H, alkyl group with one to four carbon atoms, benzyl or substituted or un-substituted aromatic base. The oxazine compound has simple synthetic method, adapts to industrialized production and is more stable when compared with natural analogues. Shown by biological activity assay, the oxazine compound has the functions of analgesia, anti-inflammatory and antithrombin activity and is a platelet aggregation inhibiting medicament.
Description
technical field [0001] The invention belongs to the technical field of medicine, and relates to oxazine compounds and their anti-platelet aggregation application. Background technique [0002] Clinical studies have shown that common cardiovascular and cerebrovascular diseases such as hypertension, diabetes, angina pectoris, myocardial infarction, cerebral infarction and cerebral hemorrhage are all related to changes in platelet function and abnormal blood rheology (Tianjin Medicine, 1992, 20 (11):684). Therefore, preventing platelet aggregation is of great significance. [0003] Platelets are produced by the lysis of mature megakaryocytes in the bone marrow. The newly formed platelets are large in size, have the ability to synthesize proteins, have strong adhesion, are easy to aggregate and release reactions, and have hemostatic function. At present, it is believed that the physiological activities of platelets mainly include three aspects: adhesion, aggregation and releas...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more